Lenvima (lenvatinib) — Medica

Initial criteria

• age ≥ 18 years
• Patient has unresectable or metastatic melanoma
• Medication is used in combination with Keytruda (pembrolizumab intravenous injection)
• Patient has disease progression on anti-programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1)-based therapy (e.g., Opdivo + Yervoy, Opdualag, Keytruda, Opdivo)

Approval duration

1 year